Research Reports

Prepared Highlights

Q4 2025 total revenues $121M, +27% YoY; full-year 2025 total revenues $428M (CFO)
Exome & genome (E&G) revenues Q4 $104M, +32% YoY; organic growth 42% excluding prior-year $6.8M one-time recovery (CFO)
E&G test results Q4 27,761, +34% YoY; quarterly growth accelerating from 24% (Q1) to 34% (Q4) (CFO)
Full-year 2025 adjusted gross margin 71% (vs 65% in 2024, 45% in 2023) (CFO)
Q4 2025 adjusted net income $4.4M; full-year 2025 adjusted net income $4.8M (CFO)
Average reimbursement rate (ARR) for E&G in Q4 approximately $3,750; full-year progression: $2,500 (2023) → $3,000 (2024) → $3,750 (2025) (CFO)
GeneDx Infinity dataset: >2.5M rare genetic tests, >1M exomes & genomes, >8M phenotypic data points; >60% of exomes/genomes have parental data; >50% of patients non-European descent (CEO)
~80% share among clinical geneticists (CEO); ~30% of pediatric neurologists reached (CFO); new expansion markets still in single-digit clinician adoption (CEO)
Sales force expanding from ~50 reps (2025) to 75 dedicated specialist reps + 50 reps for general pediatricians + 10 NICU reps + 10 prenatal reps + 5 international reps in 2026 (CEO / CFO)
Hereditary cancer testing line wound down Q3 2025; that line generated $2M in Q1 2025 and $5M in FY2025 (CFO)
Official guidance: FY2026 total revenues $540M–$555M; E&G volume growth 33%–35% (baseline 33% Q1); adjusted gross margin ~70%; adjusted net income positive for full year and each quarter; adjusted operating margin building to double digits by Q4 (CFO)
Mgmt quotes:
- "2026 is going to be a breakout year for GeneDx Holdings Corp." (CEO)
- "No one does this at the scale we do, and that is because of GeneDx Infinity." (CEO)
- "By introducing our services to mainstream clinicians, we are seizing a massive growth opportunity." (CEO)
- "We are confident in our plan to deliver." (CFO)
- "Rare disease and genomic medicine are having their moment." (Kevin Feeley, CFO, referencing Katherine Stueland’s TIME 100 Health honor)

Prepared Metrics

Metric	Value	Speaker/Context
Total revenues Q4 2025	$121M	CFO
Total revenues FY2025	$428M	CEO
E&G revenues Q4 2025	$104M (+32% YoY, organic 42%)	CFO
E&G test results Q4 2025	27,761 (+34% YoY)	CFO
Adjusted gross margin FY2025	71%	CFO
Exome & genome ARR Q4 2025	~$3,750	CFO
Adjusted net income Q4 2025	$4.4M	CFO
Adjusted net income FY2025	$4.8M	CFO
Sales force plan 2026	~50 → 135+ total reps	CEO/CFO
FY2026 revenue guidance	$540M–$555M	CFO
FY2026 E&G volume growth guidance	33%–35% (Q1 baseline 33%)	CFO
FY2026 adjusted gross margin guidance	~70%	CFO

Q&A Batch (6-10 of 10)

Q6 — Kevin Feeley (回答 Daniel Gregory Brennan)

Topic: 2026年营收指引假设——Medi-Cal、新Medicaid州、新市场（NICU/产前/儿科）的保守估计
Key points:
- 指引完全排除Medi-Cal收入（政策11月生效但缺乏定价），并假设零新Medicaid州上线。
- 新市场（儿科神经、NICU、产前）采用保守模型：参考2023年儿科神经最初两个季度拒赔率约70%（赔付率30%），现该市场赔付率已改善至“高50%以上”，以此预估新市场初期赔付率。
- 新增长驱动因素占ARR指引7%–8%，排序：NICU为首（2026年最大贡献，年初利用率提升），其次为产前（Q1零贡献，Q2少量，Q3开始爬坡），儿科神经最保守。
Mgmt stance: 谨慎（故意将不确定因素排除在指引外，等待更多数据后再调整）

Q7 — Tycho W. Peterson

Topic: 联邦/州立法进展、Pharma业务扩张策略与竞争环境
Key points:
- 联邦法案（H.R.7118《Genomic Answers for Children Act》等）2026年无影响，可能为2027年驱动因素；公司参与约30家机构推动该法案。
- Pharma业务：聚焦成人发病条件，合作方式包括赞助检测、患者匹配、临床试验匹配；数据库中有2,300名患者（客户寻求400名），挑战此前有限患病率认知。
- 竞争：销售团队规模是第二大竞争对手的6倍（仅加州销售代表人数即超过某公司全国团队）；NICU积极信号可能提前招聘更多销售代表。
Mgmt stance: 中立偏积极（立法未计入短期预期但进展良好；Pharma对话转向大型合作；竞争被视作市场验证且公司规模领先）

Q8 — Keith Hinton (Mark Anthony Massaro)

Topic: 基础市场（遗传学家）增长来源与渗透率上限争议
Key points:
- 基础市场增长依赖多年代证与指南扩展，无全新重大适应症推出；公司已从过去三年仅聚焦三种罕见病扩展至数千种。
- 遗传学家中渗透率约30%（300,000例/年），公司认为长期全基因组将取代单/多基因面板，停止诊断“奥德赛”；当前未强行转化全部需求量以保障支付。
Mgmt stance: 强烈看涨（认为处于“世代更替”早期，单/多基因面板应被淘汰）

Q9 — Brandon Couillard

Topic: 2026年运营利润率季度轨迹
Key points:
- Q1预计接近盈亏平衡（非亏损），之后全年利润率逐步上升；Q4目标达到双位数运营利润率。
- 销售代表招聘前置，因此初始季度费用较高，随代表产能成熟利润改善。
Mgmt stance: 谨慎乐观（Q1近盈亏平衡但